Quantcast

Latest aTyr Pharma Stories

2014-07-17 16:25:53

Publication in Science Unveils Novel, Diverse and Separate Biological Functions That Can Be Harnessed Therapeutically to Mediate a Wide Range of Human Disease SAN DIEGO and HONG KONG, July 17, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise, and its subsidiary in Hong Kong, Pangu Biopharma (aTyr), announced the discovery of a new class of human proteins with therapeutic relevance for a wide range of diseases. The findings unveiled today in a...

2014-07-15 00:20:40

SAN DIEGO, July 14, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise announced today, the scientific publication of a splice variant of a tRNA synthetase in association with a rare muscle disease. This article, published in the Journal of Biological Chemistry, demonstrated novel findings relative to Physiocrine proteins, that include extracellular functions derived from the tRNA synthetase gene family. These data further highlight the potential...

2014-05-21 08:29:06

First Demonstration of Safety and Tolerability of Physiocrines SAN DIEGO, May 21, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise, announced today completion of Phase 1 for its lead program, Resokine IV. Our study, which marked the first ever administration of a Physiocrine to humans, was conducted in healthy male and female subjects in the European Union to assess the safety and tolerability of Resokine IV. aTyr Pharma is developing Resokine IV...

2014-03-28 08:26:50

Clinical Leader Brings Strong Drug Development Background and Expertise SAN DIEGO, March 28, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), a rare disease biotherapeutics enterprise, announced today that David M. Weiner, M.D., joined aTyr as chief medical officer. Dr. Weiner held key leadership positions at Proteostasis, Merck Serono and Acadia Pharmaceuticals. His background includes rare disease and extensive clinical trial experience. Dr. Weiner will spearhead aTyr's efforts to...

2014-03-28 08:26:48

SAN DIEGO, March 28, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), a rare disease biotherapeutics enterprise, announced today the appointment of Ed Penhoet, Ph.D., to the Company's board of directors (BOD). Dr. Penhoet, who co-founded Chiron, is an accomplished scientist and biotech pioneer. He has served on the Independent Citizens Oversight Committee (ICOC) for the California Institute of Regenerative Medicine (CIRM) and was recently appointed to President Obama's Council of...

2014-02-24 08:28:17

First Administration to Human Subjects of a New Protein Class, Physiocrines SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- aTyr Pharma, a rare disease therapeutics enterprise, announced today the first administration of Resokine IV to healthy human volunteers. The study is being conducted in healthy male and female volunteers in the European Union. aTyr plans to develop Resokine IV as a potential therapeutic for rare disorders where a patient's immune system is imbalanced. Resokine belongs...

2014-02-05 08:29:22

Strategic Business Leader Brings Complementary Product Commercialization and Rare Disease Expertise SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), an innovative biotherapeutics enterprise, announced today that Frederic Chereau has joined aTyr as president and chief operating officer. Mr. Chereau has more than 20 years of experience in bringing new rare disease products to market and has held key leadership positions at Shire and Genzyme. Mr. Chereau's appointment will...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related